Pilbara Minerals Limited
Pilbara Minerals (ASX: PLS) is a metals and mining sector company with a special bent towards the exploration of lithium and tantalum metals. On April 1st, 2019 the PLS stock closed the market trading at a price of AUD 0.740, diving 6.33% by AUD 0.050 with around 23.62 million shares traded. On March 28th, 2019, the company announced that it is in the process of finalizing partners for Stage 3 Pilgangoora offtake.
Also, Pilbara Minerals is currently considering selling a minority interest (20% to 49%) in its premier Pilgangoora Lithium-Tantalum Project located in Western Australia. This follows the recently completed positive Stage 3 Scoping Study that revealed a compelling long-term growth trajectory.
Recently, Pilbara Minerals declared commercial production at its flagship project after steady volumes of spodumene concentrate produced over the December and March quarters of FY2019 at Pilgangoora. On March 26th, 2019, the company updated the receipt of AUD 50 million (equity placement) from Jiangxi Ganfeng Lithium Co. Ltd under the previously announced Subscription Agreement in lieu of a debt facility for Ganfeng to secure an additional 75,000 tpa of spodumene concentrate.
Leigh Creek Energy Limited
The Adelaide-based Leigh Creek Energy Limited (ASX: LCK) is an emerging energy company focussing primarily on developing its Leigh Creek Energy project (LCEP) situated in the north of Adelaide, South Australia. It explores for coal and synthesis gas including hydrogen, carbon monoxide, and methane. With the end of the trading session on April 1st, 2019, the LCK stock price soared by 10.94% and closed the market trading at AUD 0.355 with ~ 12.66 million shares traded. Besides, LCK has generated a stellar YTD return of 166.67% this year.
On March 28th, 2019, the company reported a key milestone with the assignment of a PRMS certification of 1,153 PJ 2P at the LCEP from the US-based MHA Petroleum Consultants. Currently, LCK is deciding on the possible commercial paths for the project and advancing with its negotiations with potential JV partners on investment structures as well as funding avenues. Recently, the company also closed an oversubscribed pro-rata one-for-fifteen non-renounceable rights issue receiving strong support from shareholders and investors and raised around AUD 3.86 million of funds for working capital.
engage: BDR Limited
The Melbourne-based engage:BDR Limited (ASX: EN1) operates as an Internet-based marketplace platform and technology solution provider in Australia, the United States, and other countries worldwide. On April 1st, 2019, the EN1 stock closed market trading at the last sell-off price of AUD 0.042, mounting 10.53% by AUD 0.004 with ~ 114.53 million shares traded. EN1 has also generated a high positive YTD return of 153.33% so far.
On the same day, the company provided a revenue update on the recently activated publisher integrations through a deployment of AUD 1.1 million, which initially yielded USD 20k per day. With the close of Q1 2019, EN1 has witnessed much stronger demand than previously anticipated and the recent daily programmatic revenue average over the past seven days has scaled to greater than USD 28k per day. Reportedly, the revenue grew by an average of 40% within the past seven days, while sustaining ~41% gross profit margins.
For the entire CY2018, EN1 posted revenue of AUD 11.4 million with nEBITDA of AUD 2.4 million. The company closed Q4 CY2018 with cash and cash equivalents of AUD 320K.
Bard1 Life Sciences Limited
BARD1 Life Sciences Limited (ASX: BD1) is an Australian medical technology company engaged in the development and commercialisation of non-invasive diagnostic tests for the early detection of cancer. It owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. On April 1st, 2019, the BD1 stock price soared by 37.5% to AUD 0.022 with ~ 58.11 million shares traded.
Meanwhile, BARD1 reverted ASX on a price and volume query concerning the change in BD1’s share price from a close of AUD 0.016 on March 29TH, 2019 to an intraday high of AUD 0.02 on April 1st, 2019. The company believes that the progress of the Assay Development program with its contract partner Thermo Fisher Scientific to transfer and develop the research BARD1 assay using ProcartaPlex® Technology for performance on Luminex® instrumentation could be a possible explanation. The clinical performance for the same will be evaluated in 2H 2019 followed by expected launch as Laboratory Developed Tests (LDTs) in 2021.
For the half year ended December 31st, 2018, BARD1 Life Sciences recorded a loss from ordinary activities after income tax at $ 879,642, up 13.8% on the previous corresponding period. The net cash at hand stood at AUD 3.71 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.